New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
05:38 EDTACT, FRXActavis expected to seek more deals, WSJ reports
Actavis's (ACT) move to pay $25B for Forest Labs (FRX) shows the company continues to have a strong desire for takeovers, reports the Wall Street Journal. A key consideration, sources say, was its desire to absorb more players in the fragmented generic- and specialty-pharmaceuticals industries. Actavis is paying for Forest with cash and stock in part to keep its leverage ratios low enough so that the newly merged company has the firepower to make additional acquisitions as soon as the deal closes in the next three-to-four months, sources added. Reference Link
News For ACT;FRX From The Last 14 Days
Check below for free stories on ACT;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information
July 9, 2014
06:49 EDTACTGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
July 8, 2014
16:11 EDTACTActavis files ANDA for Dalfampridine tablets
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use